Full Generic Medicine Info
Dosage/Direction for Use

Chronic hepatitis B
Adult: 600 mg once daily.
Renal impairment: ESRD: 600 mg 96 hrly, after dialysis session.
CrCl (ml/min)Dosage Recommendation
<30 (not requiring dialysis)600 mg 72 hrly.
30-49600 mg 48 hrly.
May be taken with or without food.
Hypersensitivity. Lactation. Concurrent use w/ peginterferon alfa-2a.
Special Precautions
Patient w/ cirrhosis, hepatomegaly or other risk factors for liver disease. Renal impairment. Pregnancy. Monitoring Parameters Monitor hepatic function (e.g. AST and ALT) periodically during therapy and for several mth following discontinuation of therapy; renal function; signs and symptoms of peripheral neuropathy or myopathy; serum creatine kinase; hepatitis B virus (HBV) DNA 3-6 mthly during therapy; HBeAg and anti-HBe signs/symptoms of HBV relapse/exacerbation after discontinuation of therapy.
Adverse Reactions
Cough, dizziness, fatigue, GI effects (e.g. abdominal pain, diarrhoea, nausea, vomiting, dyspepsia), rash, arthralgia, myalgia, myopathy, malaise, back pain, nasopharyngitis, headache, flu or flu-like symptoms, insomnia; increased serum amylase, lipase, creatine phosphokinase, alanine aminotransferase levels; peripheral neuropathy, rhabdomyolysis.
Potentially Fatal: Lactic acidosis, severe hepatomegaly w/ steatosis.
Drug Interactions
Altered plasma concentration w/ drugs that affect renal function (e.g. aminoglycosides, loop diuretics, platinum compounds, vancomycin, amphotericin B). May increase risk of myopathy w/ other drugs associated w/ myopathy (e.g. azole antifungals, ciclosporin, corticosteroids, erythromycin, fibrates, HMG-CoA reductase inhibitors, penicillamine, zidovudine).
Potentially Fatal: Increased risk of peripheral neuropathy w/ peginterferon alfa-2a.
Telbivudine is phosphorylated intracellularly to the active triphosphate form, which competes w/ thymidine 5'-triphosphate, the natural substrate of hepatitis B virus (HBV) reverse transcriptase, resulting to DNA chain termination and inhibition of HBV replication.
Absorption: Absorbed from the GI tract. Time to peak plasma concentration: Approx 3 hr.
Distribution: Widely distributed into tissues. Plasma protein binding: Approx 3.3%.
Metabolism: Undergoes phosphorylation by cellular kinases to form the active metabolite, telmivudine-5'-triphosphate.
Excretion: Via urine, as unchanged drug. Terminal elimination half-life: 30-53.6 hr.
Oral: Store at 25°C.
CIMS Class
ATC Classification
J05AF11 - telbivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on telbivudine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in